• Je něco špatně v tomto záznamu ?

FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer

D. Rožková, H. Tišerová, J. Fučíková, J. Lašťovička, M. Podrazil, H. Ulčová, V. Budínský, J. Prausová, Z. Linke, I. Minárik, A. Šedivá, R. Špíšek, J. Bartůňková

. 2009 ; 131 (1) : 1-10.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc11009458
E-zdroje

NLK ScienceDirect (archiv) od 1999-01-01 do 2009-12-31

Immunotherapy has emerged as another treatment modality in cancer. The goal of immunotherapy in advanced cancer patients does not have to be the complete eradication of tumor cells but rather the restoration of a dynamic balance between tumor cells and the immune response. Appropriate combination of tumor mass reduction (by surgery and/or chemotherapy) and neutralization of tumor-induced immunosuppression might set the right conditions for the induction of anti-tumor immune response by active immunotherapy. We review experimental basis and key concepts of combined chemo-immunotherapy and document its principles in the case report of patient with hormone refractory metastatic prostate cancer with sinister prognosis. More than four hundred prostate cancer patients have been treated with DC-based immunotherapy and tumor-specific immune responses have been reported in two-thirds of them. In half of these patients, DC immunotherapy resulted in transient clinical responses. Tregs, among other factors, potently inhibit tumor-specific T cells. Prostate cancer patients have elevated numbers of circulating and tumor infiltrating Tregs and there is evidence that Tregs increase tumor growth in vivo. Because of the high frequency of circulating Tregs in our patients, we first administered metronomic cyclophosphamide. After obtaining IRB approval, we started regular vaccinations with dendritic cells (DCs) loaded with killed prostate cancer cells. In accordance with the principles of combined immunotherapy, we continued palliative chemotherapy with docetaxel to reduce the tumor cell burden. DC-based vaccination induced prostate cancer cell-specific immune response. Combined chemo-immunotherapy consisting of alternate courses of chemotherapy and vaccination with mature DCs pulsed with LNCap prostate cancer cell line led to the marked improvement in the clinical and laboratory presentation and to the decrease of PSA levels by more than 90%.

000      
03905naa 2200517 a 4500
001      
bmc11009458
003      
CZ-PrNML
005      
20121102102629.0
008      
110510s2009 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rožková, Daniela, $d 1979- $7 xx0118296
245    10
$a FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer / $c D. Rožková, H. Tišerová, J. Fučíková, J. Lašťovička, M. Podrazil, H. Ulčová, V. Budínský, J. Prausová, Z. Linke, I. Minárik, A. Šedivá, R. Špíšek, J. Bartůňková
314    __
$a Institute of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic.
520    9_
$a Immunotherapy has emerged as another treatment modality in cancer. The goal of immunotherapy in advanced cancer patients does not have to be the complete eradication of tumor cells but rather the restoration of a dynamic balance between tumor cells and the immune response. Appropriate combination of tumor mass reduction (by surgery and/or chemotherapy) and neutralization of tumor-induced immunosuppression might set the right conditions for the induction of anti-tumor immune response by active immunotherapy. We review experimental basis and key concepts of combined chemo-immunotherapy and document its principles in the case report of patient with hormone refractory metastatic prostate cancer with sinister prognosis. More than four hundred prostate cancer patients have been treated with DC-based immunotherapy and tumor-specific immune responses have been reported in two-thirds of them. In half of these patients, DC immunotherapy resulted in transient clinical responses. Tregs, among other factors, potently inhibit tumor-specific T cells. Prostate cancer patients have elevated numbers of circulating and tumor infiltrating Tregs and there is evidence that Tregs increase tumor growth in vivo. Because of the high frequency of circulating Tregs in our patients, we first administered metronomic cyclophosphamide. After obtaining IRB approval, we started regular vaccinations with dendritic cells (DCs) loaded with killed prostate cancer cells. In accordance with the principles of combined immunotherapy, we continued palliative chemotherapy with docetaxel to reduce the tumor cell burden. DC-based vaccination induced prostate cancer cell-specific immune response. Combined chemo-immunotherapy consisting of alternate courses of chemotherapy and vaccination with mature DCs pulsed with LNCap prostate cancer cell line led to the marked improvement in the clinical and laboratory presentation and to the decrease of PSA levels by more than 90%.
590    __
$a bohemika - dle Pubmed
650    _2
$a adenokarcinom $x sekundární $x terapie $7 D000230
650    _2
$a senioři $7 D000368
650    _2
$a antitumorózní látky $x terapeutické užití $7 D000970
650    _2
$a nádory kostí $x sekundární $x terapie $7 D001859
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory závislé na hormonech $x sekundární $x terapie $7 D009376
650    _2
$a nádory prostaty $x patologie $x terapie $7 D011471
650    _2
$a financování organizované $7 D005381
700    1_
$a Hromádková, Hana, $d 1982- $7 xx0118299
700    1_
$a Fučíková, Jitka, $d 1983- $7 xx0116819
700    1_
$a Lašťovička, Jan, $d 1956- $7 xx0064149
700    1_
$a Podrazil, Michal, $d 1978- $7 xx0118288
700    1_
$a Ulčová, Hana, $d 1981- $7 xx0118298
700    1_
$a Budinský, Vít, $d 1980- $7 xx0118293
700    1_
$a Prausová, Jana, $d 1956- $7 xx0025145
700    1_
$a Linke, Zdeněk $7 xx0139978
700    1_
$a Minárik, Ivo. $7 xx0227806
700    1_
$a Šedivá, Anna, $d 1955- $7 xx0000191
700    1_
$a Špíšek, Radek, $d 1975- $7 nlk20030145288
700    1_
$a Bartůňková, Jiřina, $d 1958- $7 jn20000400093
773    0_
$t Clinical Immunology $w MED00005218 $g Roč. 131, č. 1 (2009), s. 1-10
910    __
$a ABA008 $b x $y 2
990    __
$a 20110513105406 $b ABA008
991    __
$a 20121102102634 $b ABA008
999    __
$a ok $b bmc $g 839020 $s 702843
BAS    __
$a 3
BMC    __
$a 2009 $x MED00005218 $b 131 $c 1 $d 1-10 $m Clinical immunology $n Clin Immunol
LZP    __
$a 2011-2B09/jvme

Najít záznam